logo
Keeping blood safe - a global challenge
The risk of developing cancer following successful treatment for hepatitis
Understanding HCV disease progression and the associate cost
Non-invasive assessment of liver fibrosis
HCV genome sequencing: what the clinician needs to know
Association of the -515A>G CDC6 polymorphism with risk to develop hepatocellular carcinoma in patients with chronic hepatitis C
Drug availability: what, where and when?
Global differences: what can we learn from HIV?
Boceprevir and telaprevir: what have we learned?
With Interferon
Simeprevir versus telaprevir in combination with pegylated interferon and ribavirin in HCV genotype 1-infected patients: the Phase III ATTAIN study
Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment-naive patients with HCV genotype 1: phase 3 COMMAND-3 results
Without interferon, with nucs
Interferon-free direct-acting antiviral (DAA) regimens for treatment of chronic hepatitis C
Treating decompensated cirrhotics
Treating patients before and after transplant
New DAAs and drug-drug interactions
Long-term persistence of patient-derived hepatitis B virus infection in 3D microfluidic primary hepatocyte cultures
Entecavir vs the Tenofovirs (TDF and TAF)
Interferon and add-on strategies in the treatment of chronic hepatitis B
Preventing reactivation in immunosuppressive and chemotherapy patients
An investigation of genome-wide promoter region CpG island hypermethylation profiles in patients with chronic hepatitis B virus infection
How should we monitor patients after SVR?
How do we treat acute HCV when we don't have any trial data?
HCV contributes to the aggravation suppressive activity of natural regulatory T cells and induces the emergence of type 1 regulatory T cells
HCV and insulin resistance
HCV and lymphoma
Vasculitis and its relationship to hepatitis C
The correlation between hepatitis C core antigen and HCV RNA levels with respect to HIV status, HCV genotype and IFNL4 polymorphism
Correlation of noninvasive serum fibrosis markers with stage of fibrosis in chronic hepatitis
Prevalence of the hepatitis C virus polymorphism Q80K in a pooled analysis of G1 patients from telaprevir and simeprevir phase II/III clinical trials
Birth cohort screening for hepatitis C: a comparative analysis in foreign-born versus US-born baby boomers
Epidemiological study of prevalence and risk factors for HCV among apparently healthy Mongolians
Prevalence of HCV, HBV and HIV infections among hemophiliac
Daclatasvir + sofosbuvir with or without ribavirin in patients with chronic HCV infection: interim analysis of a multicenter compassionate use program
Simeprevir with PegIFN/ribavirin for chronic HCV infection shortens time with patientreported symptoms and impairment in QoL: ATTAIN study results
Efficacy and safety of simeprevir in treatmentnaïve HCV genotype 1-infected patients with METAVIR F2 fibrosis: QUEST-1 and QUEST-2 Phase III studies
Factors associated with medical resource utilisation and related costs in treatment-experienced patients with genotype 1 chronic hepatitis C
The use of silymarin in chronic hepatitis C infection: an updated systematic review and meta-analysis
Factors associated with triple therapy discontinuation due to adverse effects among patients with hepatitis C genotype 1 chronic infection
Triple therapy with boceprevir in treatmentexperienced patients with HCV in a third-level hospital in Mexico
Renal function in HCV genotype 1-infected treatment-naïve patients receiving simeprevir in combination with Peg-IFN and ribavirin: a post-hoc analysis
The IFNL4 ΔG/TT genotyping does not improve prediction of SVR in HCV-infected patients in the Czech Republic
Restoration of innate immune responses may be a novel therapeutic strategy for treatment of chronic hepatitis C virus infection
Role of interferon lambda-4 and inosine triphosphatase polymorphisms in the treatment of Thai patients with chronic hepatitis C virus genotype 3
Effect of antidepressant drug use on virological response during the treatment of chronic hepatitis C
IDX21437, a novel nucleotide analogue prodrug HCV NS5B polymerase inhibitor
The effect of renal impairment on single-dose pharmacokinetics of daclatasvir, an HCV NS5A inhibitor
Computational identification of rare codon clusters in hepatitis C virus: a bioinformatic look
Identification and expression profiling of microRNAs in hepatitis C patients by using next generation sequencing
A novel non-invasive biological predictive index (Khattab index) for liver fibrosis in hepatitis C virus (HCV) genotype 4 patients
Health-Related Quality of Life and productivity impairment in chronic hepatitis C patients in Germany
Chronic hepatitis C - a 7-year experience
Hyperlipidemia in chronic hepatitis C under triple therapy with boceprevir
T and B cell responses and previous exposure to hepatitis B virus in ‘anti-HBc alone’ patients
Status for hepatitis B virus infection and socioeconomic variables: a multiple correspondence analysis
Epidemiological study of prevalence and risk factors for HBV among apparently healthy Mongolians
Entecavir has high efficacy and safety in Caucasian patients with chronic hepatitis B and co-morbidities
Preventing HBV reactivation: an automated prompt to remind oncologists to screen was only partially successful
Investigation of factors affecting time to initiation of hepatitis B virus treatment
Molecular characterizations of hepatitis B escape mutants among blood donors in Malaysia
Cryptic HBV, HCV and HEV infection in presumed nonA-E hepatitis
Evaluation of interleukin-10 gene promoter polymorphism (-819 C/T) in patients with chronic hepatitis B virus infection
Lack of association between interleukin-27 gene polymorphisms (-964 A/G, 2905 T/G) and chronic hepatitis B virus infection
Genetic polymorphisms of interleukin-17 (rs2275913, rs2397084) and susceptibility to chronic hepatitis B virus infection
Autophagy evaluation in chronic liver disease progression
Therapeutic drug monitoring of ribavirin predicts SVR and development of anemia in boceprevir-based triple regimens
Anti-fibrotic effect of Smad decoy oligodeoxynucleotide in carbon tetrachlorideinduced hepatic fibrosis
Protective effects of NF-KB decoy oligodeoxynucleotide on liver fibrosis through regulation of epithelial-mesenchymal transition
Assessment of triple infections of HIV, TB and hepatitis (B and C); and associated risk factors in selected district of North Wollo Zone, Ethiopia
Is recipient interleukin-28B (rs12979860) polymorphism associated with clinically recurrent HCV after living donor liver transplantation?
Slow response to antiviral therapy in liver transplant recipients
Virological characteristics of hepatitis E and A infection in acute sporadic viral hepatitis and acute exacerbation of chronic liver disease patients
Different results of prevalence of hepatitis E specific antibodies if determined by three EIA tests
Clinical burden of hepatitis E infections in Belgium
Acute HEV infection in liver transplant recipients: safety and efficacy of ribavirin therapy
Investigation of hepatitis A outbreaks at SMKN 2 Depok, West Java in October 2011